Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

Patmore, Lesley A.; van Eekhout, Kirsi M.A.; Buti, Maria; Koc, Özgur.M.; Agarwal, Kosh; de Knegt, Rob J.; Janssen, Harry L.A.; van der Valk, Marc; Lieveld, Faydra I.; Hansen, Bettina E.; Kramer, Matthijs; de Bruijne, Joep; Claassen, Mark A.A.; Smit, Colette; de Man, Rob A.; Takkenberg, Bart; Carey, Ivana; Sonneveld, Milan J.

doi:10.1016/j.jhep.2023.10.019

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is particularly noteworthy that the effectiveness of the PAGE-B score in predicting HCC has not been thoroughly evaluated in patients of African origin, a population in which CHB is a significant cause of morbidity and mortality. A recent study by Patmore et al [ 43 ] highlighted the association between HCC incidence and varying levels of the PAGE-B score in hepatitis B patients of African descent. Specifically, the risk of HCC was negligible among individuals without advanced fibrosis and a low baseline (m)PAGE-B score.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of PAGE-B Score for Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients: Reliability, Validity, and Responsiveness

Tourkochristou,

Kalafateli,

Triantos

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) constitutes a major global public health issue, affecting millions of individuals. Despite the implementation of robust vaccination programs, the hepatitis B virus (HBV) significantly influences morbidity and mortality rates. CHB emerges as one of the leading causes of hepatocellular carcinoma (HCC), introducing a major challenge in the effective management of CHB patients. Therefore, it is of utmost clinical importance to diligently monitor individuals with CHB who are at high risk of HCC development. While various prognostic scores have been developed for surveillance and screening purposes, their accuracy in predicting HCC risk may be limited, particularly in patients under treatment with nucleos(t)ide analogues. The PAGE-B model, incorporating age, gender, and platelet count, has exhibited remarkable accuracy, validity, and reliability in predicting HCC occurrence among CHB patients receiving HBV treatment. Its predictive performance stands out, whether considered independently or in comparison to alternative HCC risk scoring systems. Furthermore, the introduction of targeted adjustments to the calculation of the PAGE-B score might have the potential to further improve its predictive accuracy. This review aims to evaluate the efficacy of the PAGE-B score as a dependable tool for accurate prediction of the development of HCC in CHB patients. The evidence discussed aims to provide valuable insights for guiding recommendations on HCC surveillance within this specific population.

show abstract

Section: Discussionmentioning

confidence: 99%